Photodynamic therapy for cancer and activation of immune response

Pawel A Mroz, Ying Ying Huang, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

5 Citations (Scopus)

Abstract

Anti-tumor immunity is stimulated after PDT for cancer due to the acute inflammatory response, exposure and presentation of tumor-specific antigens, and induction of heat-shock proteins and other danger signals. Nevertheless effective, powerful tumor-specific immune response in both animal models and also in patients treated with PDT for cancer, is the exception rather than the rule. Research in our laboratory and also in others is geared towards identifying reasons for this sub-optimal immune response and discovering ways of maximizing it. Reasons why the immune response after PDT is less than optimal include the fact that tumor-antigens are considered to be self-like and poorly immunogenic, the tumor-mediated induction of CD4+CD25+foxP3+ regulatory T-cells (T-regs), that are able to inhibit both the priming and the effector phases of the cytotoxic CD8 T-cell anti-tumor response and the defects in dendritic cell maturation, activation and antigen-presentation that may also occur. Alternatively-activated macrophages (M2) have also been implicated. Strategies to overcome these immune escape mechanisms employed by different tumors include combination regimens using PDT and immunostimulating treatments such as products obtained from pathogenic microorganisms against which mammals have evolved recognition systems such as PAMPs and toll-like receptors (TLR). This paper will cover the use of CpG oligonucleotides (a TLR9 agonist found in bacterial DNA) to reverse dendritic cell dysfunction and methods to remove the immune suppressor effects of T-regs that are under active study.

Original languageEnglish (US)
Title of host publicationBiophotonics and Immune Responses V
Volume7565
DOIs
StatePublished - May 3 2010
Externally publishedYes
EventBiophotonics and Immune Responses V - San Francisco, CA, United States
Duration: Jan 25 2010Jan 25 2010

Other

OtherBiophotonics and Immune Responses V
CountryUnited States
CitySan Francisco, CA
Period1/25/101/25/10

Fingerprint

Photodynamic therapy
Photochemotherapy
Tumors
therapy
tumors
cancer
Chemical activation
activation
antigens
Antigens
Neoplasms
T-cells
Neoplasm Antigens
Dendritic Cells
induction
Bacterial DNA
Mammals
priming
Macrophages
effectors

Keywords

  • Anti-tumor immunity
  • CpG oligonucleotides
  • Low dose cyclophosphamide
  • Photodynamic therapy
  • Regulatory T-cells

Cite this

Mroz, P. A., Huang, Y. Y., & Hamblin, M. R. (2010). Photodynamic therapy for cancer and activation of immune response. In Biophotonics and Immune Responses V (Vol. 7565). [756503] https://doi.org/10.1117/12.841031

Photodynamic therapy for cancer and activation of immune response. / Mroz, Pawel A; Huang, Ying Ying; Hamblin, Michael R.

Biophotonics and Immune Responses V. Vol. 7565 2010. 756503.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mroz, PA, Huang, YY & Hamblin, MR 2010, Photodynamic therapy for cancer and activation of immune response. in Biophotonics and Immune Responses V. vol. 7565, 756503, Biophotonics and Immune Responses V, San Francisco, CA, United States, 1/25/10. https://doi.org/10.1117/12.841031
Mroz PA, Huang YY, Hamblin MR. Photodynamic therapy for cancer and activation of immune response. In Biophotonics and Immune Responses V. Vol. 7565. 2010. 756503 https://doi.org/10.1117/12.841031
Mroz, Pawel A ; Huang, Ying Ying ; Hamblin, Michael R. / Photodynamic therapy for cancer and activation of immune response. Biophotonics and Immune Responses V. Vol. 7565 2010.
@inproceedings{d7f4af0d0ed1407fbceaadedb88f877e,
title = "Photodynamic therapy for cancer and activation of immune response",
abstract = "Anti-tumor immunity is stimulated after PDT for cancer due to the acute inflammatory response, exposure and presentation of tumor-specific antigens, and induction of heat-shock proteins and other danger signals. Nevertheless effective, powerful tumor-specific immune response in both animal models and also in patients treated with PDT for cancer, is the exception rather than the rule. Research in our laboratory and also in others is geared towards identifying reasons for this sub-optimal immune response and discovering ways of maximizing it. Reasons why the immune response after PDT is less than optimal include the fact that tumor-antigens are considered to be self-like and poorly immunogenic, the tumor-mediated induction of CD4+CD25+foxP3+ regulatory T-cells (T-regs), that are able to inhibit both the priming and the effector phases of the cytotoxic CD8 T-cell anti-tumor response and the defects in dendritic cell maturation, activation and antigen-presentation that may also occur. Alternatively-activated macrophages (M2) have also been implicated. Strategies to overcome these immune escape mechanisms employed by different tumors include combination regimens using PDT and immunostimulating treatments such as products obtained from pathogenic microorganisms against which mammals have evolved recognition systems such as PAMPs and toll-like receptors (TLR). This paper will cover the use of CpG oligonucleotides (a TLR9 agonist found in bacterial DNA) to reverse dendritic cell dysfunction and methods to remove the immune suppressor effects of T-regs that are under active study.",
keywords = "Anti-tumor immunity, CpG oligonucleotides, Low dose cyclophosphamide, Photodynamic therapy, Regulatory T-cells",
author = "Mroz, {Pawel A} and Huang, {Ying Ying} and Hamblin, {Michael R.}",
year = "2010",
month = "5",
day = "3",
doi = "10.1117/12.841031",
language = "English (US)",
isbn = "9780819479617",
volume = "7565",
booktitle = "Biophotonics and Immune Responses V",

}

TY - GEN

T1 - Photodynamic therapy for cancer and activation of immune response

AU - Mroz, Pawel A

AU - Huang, Ying Ying

AU - Hamblin, Michael R.

PY - 2010/5/3

Y1 - 2010/5/3

N2 - Anti-tumor immunity is stimulated after PDT for cancer due to the acute inflammatory response, exposure and presentation of tumor-specific antigens, and induction of heat-shock proteins and other danger signals. Nevertheless effective, powerful tumor-specific immune response in both animal models and also in patients treated with PDT for cancer, is the exception rather than the rule. Research in our laboratory and also in others is geared towards identifying reasons for this sub-optimal immune response and discovering ways of maximizing it. Reasons why the immune response after PDT is less than optimal include the fact that tumor-antigens are considered to be self-like and poorly immunogenic, the tumor-mediated induction of CD4+CD25+foxP3+ regulatory T-cells (T-regs), that are able to inhibit both the priming and the effector phases of the cytotoxic CD8 T-cell anti-tumor response and the defects in dendritic cell maturation, activation and antigen-presentation that may also occur. Alternatively-activated macrophages (M2) have also been implicated. Strategies to overcome these immune escape mechanisms employed by different tumors include combination regimens using PDT and immunostimulating treatments such as products obtained from pathogenic microorganisms against which mammals have evolved recognition systems such as PAMPs and toll-like receptors (TLR). This paper will cover the use of CpG oligonucleotides (a TLR9 agonist found in bacterial DNA) to reverse dendritic cell dysfunction and methods to remove the immune suppressor effects of T-regs that are under active study.

AB - Anti-tumor immunity is stimulated after PDT for cancer due to the acute inflammatory response, exposure and presentation of tumor-specific antigens, and induction of heat-shock proteins and other danger signals. Nevertheless effective, powerful tumor-specific immune response in both animal models and also in patients treated with PDT for cancer, is the exception rather than the rule. Research in our laboratory and also in others is geared towards identifying reasons for this sub-optimal immune response and discovering ways of maximizing it. Reasons why the immune response after PDT is less than optimal include the fact that tumor-antigens are considered to be self-like and poorly immunogenic, the tumor-mediated induction of CD4+CD25+foxP3+ regulatory T-cells (T-regs), that are able to inhibit both the priming and the effector phases of the cytotoxic CD8 T-cell anti-tumor response and the defects in dendritic cell maturation, activation and antigen-presentation that may also occur. Alternatively-activated macrophages (M2) have also been implicated. Strategies to overcome these immune escape mechanisms employed by different tumors include combination regimens using PDT and immunostimulating treatments such as products obtained from pathogenic microorganisms against which mammals have evolved recognition systems such as PAMPs and toll-like receptors (TLR). This paper will cover the use of CpG oligonucleotides (a TLR9 agonist found in bacterial DNA) to reverse dendritic cell dysfunction and methods to remove the immune suppressor effects of T-regs that are under active study.

KW - Anti-tumor immunity

KW - CpG oligonucleotides

KW - Low dose cyclophosphamide

KW - Photodynamic therapy

KW - Regulatory T-cells

UR - http://www.scopus.com/inward/record.url?scp=77951553485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951553485&partnerID=8YFLogxK

U2 - 10.1117/12.841031

DO - 10.1117/12.841031

M3 - Conference contribution

SN - 9780819479617

VL - 7565

BT - Biophotonics and Immune Responses V

ER -